EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
ENHERTU® has demonstrated clinically meaningful progression-free survival and overall survival in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial.
The.
GPO Plus, Inc. (OTCQB:GPOX) shares are earning investors' attention, evidenced by an over 22% rally from its June lows. The better news- GPO Plus, Inc. is reclaiming its higher price on higher-than-average volume. That